Estudo observacional do prognóstico e terapêutica dos portadores de linfoma difuso de grandes células B e de IPIa de risco intermediário alto e alto

Neto, Hallack; Elias, A

doi:10.11606/t.5.2008.tde-29012009-092055

Cited by 2 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The BCL6 gene is a proto-oncogene located on chromosome3q27 expressed on normal B-cells in the germinal center (28-30) . The BCL6 protein blocks genes involved in cell cycle progression and response to DNA damage (8) .…”

Section: Main Oncogenes Involved In the Pathogenesis Of Dlbclmentioning

confidence: 99%

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multifactorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6, and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.

show abstract

Section: Main Oncogenes Involved In the Pathogenesis Of Dlbclmentioning

confidence: 99%

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

View full text Add to dashboard Cite

show abstract

“…Na era pré-rituximabe, melhores resultados eram obtidos em pacientes jovens com LDGCB e IPI intermediário alto ou alto com a consolidação com ATMO em primeira RC (HAIOUN et al, 2000;HALLACK NETO, 2008 -Sempre que eixo maior >1,5cm; -Quando o eixo maior está entre 1,1-1,5cm, se o menor eixo >1cm; 2. Aparecimento de nova lesão com qualquer eixo >1,5cm durante ou ao final do tratamento; 3.…”

Section: 3 Imunoterapiaunclassified

Padrão de expressão e significado prognóstico dos genes BCL2, BCL6, CCND2, FN1, LMO2 e SCYA3 pela técnica de PCR em tempo real com linfoma difuso de grandes células B tratado com rituximabe

Xavier¹

View full text Add to dashboard Cite

Estudo observacional do prognóstico e terapêutica dos portadores de linfoma difuso de grandes células B e de IPIa de risco intermediário alto e alto

Cited by 2 publications

References 24 publications

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Padrão de expressão e significado prognóstico dos genes BCL2, BCL6, CCND2, FN1, LMO2 e SCYA3 pela técnica de PCR em tempo real com linfoma difuso de grandes células B tratado com rituximabe

Contact Info

Product

Resources

About